2025
315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle Aspiration
Bernhisel A, Sun T, Prasad M, Ladenheim A, Cai G, Adeniran A. 315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle Aspiration. Laboratory Investigation 2025, 105: 102542. DOI: 10.1016/j.labinv.2024.102542.Peer-Reviewed Original Research411 Correlation of ACR-TI-RADS, Cytology, Histology, and Molecular studies
Yu S, Wang M, Langdon J, Sinard J, Cai G, Prasad M, Adeniran A. 411 Correlation of ACR-TI-RADS, Cytology, Histology, and Molecular studies. Laboratory Investigation 2025, 105: 102638. DOI: 10.1016/j.labinv.2024.102638.Peer-Reviewed Original Research401 Prognostic Value of Pelvic Washing Cytology in Early-Stage Endometrial Cancer: A 10-Year Single-Institute Cohort Study
Wang M, Abi-Raad R, Krishnamurti U, Cai G, Adeniran A, Sun T. 401 Prognostic Value of Pelvic Washing Cytology in Early-Stage Endometrial Cancer: A 10-Year Single-Institute Cohort Study. Laboratory Investigation 2025, 105: 102628. DOI: 10.1016/j.labinv.2024.102628.Peer-Reviewed Original Research351 Follicular Neoplasms: Cytomorphological Subclassification, Molecular Alterations and Risk of Malignancy
Kaur H, Gereg C, Abi-Raad R, Adeniran A, Cai G. 351 Follicular Neoplasms: Cytomorphological Subclassification, Molecular Alterations and Risk of Malignancy. Laboratory Investigation 2025, 105: 102578. DOI: 10.1016/j.labinv.2024.102578.Peer-Reviewed Original Research334 Utility of SATB2 Immunocytochemistry in the Diagnostic Workup of Cytological Specimens from Patients with Suspected Osteosarcoma
Gereg C, Cai G. 334 Utility of SATB2 Immunocytochemistry in the Diagnostic Workup of Cytological Specimens from Patients with Suspected Osteosarcoma. Laboratory Investigation 2025, 105: 102561. DOI: 10.1016/j.labinv.2024.102561.Peer-Reviewed Original Research341 Comparative Assessment of Claudin-4, MOC-31, and BerEP4 Immunomarkers in Diagnostic Workup of Metastatic Carcinoma in Serous Fluid Specimens
Haque M, Kaur H, Wang M, Cai G. 341 Comparative Assessment of Claudin-4, MOC-31, and BerEP4 Immunomarkers in Diagnostic Workup of Metastatic Carcinoma in Serous Fluid Specimens. Laboratory Investigation 2025, 105: 102568. DOI: 10.1016/j.labinv.2024.102568.Peer-Reviewed Original ResearchFine‐Needle Aspiration Biopsy of Adrenal Gland Lesions: The Roles of Image Guidance, Rapid On‐Site Evaluation and Additional Tissue Sampling
Yu S, Dolezal D, Aslanian H, Cai G. Fine‐Needle Aspiration Biopsy of Adrenal Gland Lesions: The Roles of Image Guidance, Rapid On‐Site Evaluation and Additional Tissue Sampling. Cytopathology 2025 PMID: 39878416, DOI: 10.1111/cyt.13472.Peer-Reviewed Original ResearchFine-needle aspirationDiagnosis of adrenal lesionsCytological diagnostic categoriesAdrenal lesionsIndeterminate cytological diagnosisNon-diagnostic rateCytological diagnosisEndoscopic ultrasoundEUS-FNAOn-site evaluationNon-diagnosticImage guidanceComputed tomographyCT-guided fine-needle aspirationEvaluation of adrenal lesionsFine-needle aspiration diagnosisTissue samplesFine-needle aspiration proceduresLeft adrenal lesionRight adrenal lesionRapid on-site evaluationNon-ROSE groupIncrease diagnostic yieldImage guidance methodsCore tissue biopsiesComprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas
Antony V, Sun T, Dolezal D, Cai G. Comprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas. Cancers 2025, 17: 335. PMID: 39941707, PMCID: PMC11815932, DOI: 10.3390/cancers17030335.Peer-Reviewed Original ResearchMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaPrimary pancreatic ductal adenocarcinomaMolecular profilingGene mutationsGene copy number alterationsAdvanced-stage pancreatic cancerInsufficient tumor cellsOncomine Comprehensive AssayRate of TP53Copy number alterationsMetastatic diseasePDAC casesPIK3CA mutationsPancreatic cancerPoor prognosisTreatment optionsDuctal adenocarcinomaTumor cellsTumor progressionMolecular alterationsStudy cohortMolecular testingComprehensive assayTherapeutic target
2024
TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up
Abi-Raad R, Shi Q, Chen F, Antony V, Hsiao W, Simsir A, Liu X, Brandler T, Cai G. TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up. American Journal Of Clinical Pathology 2024, 163: 251-257. PMID: 39250709, DOI: 10.1093/ajcp/aqae117.Peer-Reviewed Original ResearchTERT promoter mutationsHistopathologic follow-upFine-needle aspirationTERT mutationsMolecular alterationsFollow-upPromoter mutationsThyroid carcinomaFine-needle aspiration diagnosisFine-needle aspiration specimensThyroid fine-needle aspiration specimensBenign thyroid neoplasmsSurgical follow-upAssociated with malignancyMulti-institutional studyThyroSeq v3Thyroid neoplasmsAspiration specimensTumor behaviorMalignant neoplasmsCarcinomaMalignancyNeoplasmsThyroidMutationsCytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma
Takeda K, Adeniran A, Levi A, Tang H, Cai G. Cytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma. Cytopathology 2024, 35: 724-732. PMID: 38992916, DOI: 10.1111/cyt.13413.Peer-Reviewed Original ResearchHigh-grade papillary urothelial carcinomaLow-grade papillary urothelial carcinomaPapillary urothelial carcinomaUrothelial carcinomaVoided urine samplesCytomorphologic featuresBenign casesUrine samplesUrine specimensNuclear enlargementVoided urine specimensHigh-grade transformationNuclear-to-cytoplasmic (N/CIrregular nuclear membranesUrine cytologyRetrospective reviewHistopathological diagnosisCytomorphologic characteristicsCytomorphological distinctionFrequent recurrenceCytologic featuresCarcinomaBenign conditionsAccurate diagnosisHigh N/C ratioReevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience
Takeda K, Cai G, Adeniran A, Sun T. Reevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience. American Journal Of Clinical Pathology 2024, 162: aqae077. PMID: 38916141, DOI: 10.1093/ajcp/aqae077.Peer-Reviewed Original ResearchCystic fluid cytologyFine-needle aspirationFluid cytologyAmerican College of Obstetricians and Gynecologists guidelinesSingle-institution cohortRate of malignancySurgical pathology diagnosisFNA casesGynecologists guidelinesCytological diagnosisFNA cytologyPathological diagnosisPatient demographicsInstitutional experienceSurgical pathologyOvarian cyst fluidClinical circumstancesAmerican CollegeCytologyRadiological informationMalignancyGold standardCyst fluidModerate sensitivityPotential safety concernsThe World Health Organization Reporting System for Lung Cytopathology–A Review of the First Edition
Dolezal D, Kholová I, Cai G. The World Health Organization Reporting System for Lung Cytopathology–A Review of the First Edition. Journal Of Clinical And Translational Pathology 2024, 4: 18-35. PMID: 38736711, PMCID: PMC11086742, DOI: 10.14218/jctp.2023.00068.Peer-Reviewed Original ResearchClinical management recommendationsRisk of malignancyCytomorphologic criteriaLung cytopathologyImprove patient careAncillary testsEstimated risk of malignancyReporting SystemDiagnostic categoriesPatient carePotential diagnostic pitfallsGroup of lesionsPractice settingsManagement recommendationsPractice recommendationsDiagnostic pitfallsEstimated riskCytopathology specimensCytopathology practiceLungCytopathologyLesionsMalignancyCytopathologistsSpecimen typesImproving diagnostic yield of pancreatic serous cystadenoma with cyst fluid ancillary testing, adjunct immunohistochemistry, and additional fine‐needle biopsy sampling
Wang X, Zhang X, Hui P, Cai G. Improving diagnostic yield of pancreatic serous cystadenoma with cyst fluid ancillary testing, adjunct immunohistochemistry, and additional fine‐needle biopsy sampling. Cancer Cytopathology 2024, 132: 425-434. PMID: 38450993, DOI: 10.1002/cncy.22808.Peer-Reviewed Original ResearchDiagnosis of serous cystadenomaFine-needle biopsyFine-needle aspirationCyst fluid carcinoembryonic antigenPancreatic serous cystadenomaSerous cystadenomaAncillary testsCEA levelsCytological diagnosisFine-needle aspiration cell blocksFine-needle aspiration diagnosisFine-needle aspiration casesCyst fluid CEA levelsSerous cystadenoma casesFluid carcinoembryonic antigenLow CEA levelFine-needle biopsy samplingKRAS mutation analysisWild-type KRASConcurrent fine-needle aspirationImprove diagnostic yieldInhibin immunostainingAtypical cellsCytology casesDiagnostic yieldASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
Hu B, Wiesehöfer M, de Miguel F, Liu Z, Chan L, Choi J, Melnick M, Arnal Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, Xiao A, Yan Q, Homer R, Nguyen D, Politi K. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts. Cancer Research 2024, 84: 1303-1319. PMID: 38359163, DOI: 10.1158/0008-5472.can-23-0438.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsPatient-derived xenograftsEGFR mutant lung cancerMutant lung cancerPre-treatment tumorsResidual diseaseDrug toleranceLung cancerResidual tumor cells in vivoEGFR mutant lung adenocarcinomaTyrosine kinase inhibitor osimertinibEGFR tyrosine kinase inhibitorsTyrosine kinase inhibitor treatmentTumor cells in vivoMutant lung adenocarcinomaMaximal tumor regressionTranscription factor Ascl1Drug-tolerant cellsTime of maximal responseEvidence of cellsCells in vivoOsimertinib treatmentTumor regressionSingle cell transcriptional profilingTumor cells
2023
Respiratory Tract
Sardana R, Cai G. Respiratory Tract. 2023, 189-215. DOI: 10.1007/978-3-031-44289-6_11.Peer-Reviewed Original ResearchRespiratory tractNeedle aspirationKey cytomorphologic featuresCommon inflammatory conditionSpectrum of diagnosesTransbronchial needle aspirationFine-needle aspirationFalse-negative diagnosesBronchoalveolar lavageClinical symptomsBronchial washPulmonary pathologyInflammatory conditionsRespiratory cytologyBrush smearsCytomorphologic featuresCytological evaluationCytologic specimensInfectious diseasesDiagnosisTractDiagnostic processAspirationInitial investigationLavageLiver and Biliary Tract
Wang X, Cai G. Liver and Biliary Tract. 2023, 247-266. DOI: 10.1007/978-3-031-44289-6_14.Peer-Reviewed Original ResearchBiliary tractPrimary sclerosis cholangitisExtrahepatic biliary tractRelevant clinical historyEchinococcal cystsLiver cystsAmebic abscessClinical historyNonneoplastic lesionsNonneoplastic disordersCytomorphologic featuresBenign lesionsSolid lesionsHepatocyte hyperplasiaMalignant counterpartsInfectious entitiesLesionsCystsLiverTractCholangitisCirrhosisAbscessStentingHyperplasiaPancreas
Wang X, Cai G. Pancreas. 2023, 229-245. DOI: 10.1007/978-3-031-44289-6_13.Peer-Reviewed Original ResearchUrinary Tract Cytology
Cai G. Urinary Tract Cytology. 2023, 11-34. DOI: 10.1007/978-3-031-44289-6_2.Peer-Reviewed Original ResearchHOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B
Malvi P, Chava S, Cai G, Hu K, Zhu L, Edwards Y, Green M, Gupta R, Wajapeyee N. HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B. Cell Reports Medicine 2023, 4: 101285. PMID: 37951219, PMCID: PMC10694669, DOI: 10.1016/j.xcrm.2023.101285.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaHomeobox C6PDAC growthInsulin-like growth factor 1 receptorGrowth factor 1 receptorKinase MSK1Factor 1 receptorTranscription factorsPancreatic cancer growthMSK1Tumor growthPDAC tumor growthMost pancreatic ductal adenocarcinomasMammalian targetIGF1R inhibitorsTherapeutic vulnerabilitiesRapamycin (mTOR) pathway activationMEK inhibitor trametinibMetastasis pathwaysPDAC mouse modelPDAC cellsMTOR inhibitionPharmacological inhibitionPathway activationInhibition blocksCytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up
Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.Peer-Reviewed Original ResearchHigh-grade urothelial carcinomaLow-grade urothelial carcinomaUpper urinary tractUrothelial carcinomaUrinary tractCytologic evaluationCytology specimensInstitutional retrospective studyParis SystemHigh-grade malignancyAtypical urothelial cellsCytologic categoriesRetrospective studyInstitutional databaseCytological diagnosisUrinary cytopathologyHistopathologicMalignant cellsBenign casesUrothelial cellsTPS categoryCarcinomaReporting systemTractAUC
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply